Laboratories today announced that its wholly owned subsidiary,
Ranbaxy Pharmaceuticals Inc. (RPI), has launched pravastatin
sodium 80mg tablets in the US healthcare system.
the first-to-file, it will enjoy a 180-day exclusivity
for and benefit from the commercial gains during this
period. The annual sales for Pravastatin 80mg are $209
million, according to IMS: MAT (December 2006).
is indicated in the treatment of primary prevention
of coronary events such as in hypercholesterolemic patients
without clinically evident coronary heart disease. The
drug is also indicated in the reduction of the risk
of myocardial infarction, reduction in the risk of undergoing
myocardial revascularisation procedures and reduction
in the risk of cardiovascular mortality with no increase
in death from non-cardiovascular causes.
is also indicated for treatment in the secondary prevention
of cardiovascular events such as in patients with clinically
evident coronary heart disease to reduce the risk of
stroke and stroke / transient ischemic attack (TIA),
and slow the progression of coronary atherosclerosis.
will make Pravastatin Sodium 80mg tablets available
to all classes of trade immediately, and our sales and
distribution teams will be doing everything to have
the product in the hands of our customers as quickly
as possible," said Jim Meehan, vice president,
sales and marketing, RPI. "We are delighted to
have this product formulation as an addition to our
ever expanding product portfolio of affordable generic
alternatives," Meecham added.